Cipla Ltd (CIPLA) — shareholding pattern, promoter holding, financials and share price
About Cipla Ltd (CIPLA)
Cipla Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as CIPLA and on the BSE under scrip code 500087. Its ISIN is INE059A01026.
Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs [1]
Cipla Limited is a leading pharmaceutical company in India, engaged in manufacturing and marketing a wide range of branded and generic medications, including complex generics and active pharmaceutical ingredients (APIs).
In Q3 FY26, Cipla recorded a revenue of INR 7,074 crore, but experienced a decline in EBITDA and profit margins, driven by lower revenues from generic Revlimid.
Listed peers in Pharmaceuticals: Zydus Lifesciences Ltd, Lupin Ltd, Mankind Pharma Ltd, Dr Reddys Laboratories Ltd, Aurobindo Pharma Ltd, Laurus Labs Ltd.
Valuation & Returns
10 Jul 2026At ₹1,438.75 a share on 10 Jul 2026, Cipla Ltd (CIPLA) was valued at a price-to-earnings ratio of 30.03x against an industry P/E of 36.41x and a price-to-book of 3.38x on a book value of ₹426.22 per share as of Mar 2026. Solomo computes return on equity of 11.24% and return on capital employed of 15.06% from filed results. Earnings ratios use consolidated results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 30.03x
- Industry P/E
- 36.41x
- P/B
- 3.38x
- EPS (TTM)
- ₹47.9
- Book value / share
- ₹426.22
- ROE
- 11.24%
- ROCE
- 15.06%
- ROA
- 9.11%
- Debt / equity
- 0.02x
- Dividend yield
- 0.9%
- EBITDA margin
- 23.42%
- 52-week range
- ₹1,165.55 – ₹1,672.2
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Cipla Ltd (CIPLA) reported revenue of ₹28,163 crore, net profit of ₹3,862 crore and earnings per share of ₹48.02. That compares with revenue of ₹27,548 crore and net profit of ₹5,269 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹6,541 crore and net profit ₹543 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 21,763 | 22,753 | 25,774 | 27,548 | 28,163 |
| Net profit (₹ cr) | 2,547 | 2,833 | 4,154 | 5,269 | 3,862 |
| EPS (₹) | 31.19 | 34.71 | 51.05 | 65.28 | 48.02 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 6.28% | 10.92% | 9.78% | 5.33% |
| Profit growth | 15.31% | 11.45% | 17.92% | -26.86% |
| Stock price CAGR | 11% | 8% | 11% | -3% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 29.21% of Cipla Ltd (CIPLA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 20.21% and domestic institutional investors (DII) hold 34.63%. Market capitalisation was ₹1,16,229 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: LICI ULIP-GROWTH FUND 9.75%, HDFC TRUSTEE COMPANY LIMITED-HDFC FLEXI CAP FUND 4.48%, SBI NIFTY 50 EQUAL WEIGHT INDEX FUND 3.24%, ICICI PRUDENTIAL EQUITY SAVINGS FUND 2.36%, NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA ARB 1.96%, DSP NIFTY 50 INDEX FUND 1.9%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 29.21% | - | 20.21% | 34.63% | 70.79% |
| Mar 2026 | 29.21% | - | 22.56% | 31.97% | 70.79% |
| Dec 2025 | 29.21% | - | 23.93% | 30.72% | 70.79% |
| Sep 2025 | 29.21% | - | 24.55% | 30.25% | 70.79% |
| Jun 2025 | 29.19% | - | 25.24% | 29.26% | 70.81% |
| Mar 2025 | 29.2% | - | 26.28% | 28.15% | 70.8% |
| Dec 2024 | 29.19% | - | 26.65% | 27.71% | 70.81% |
| Sep 2024 | 30.92% | - | 28.8% | 24.16% | 69.08% |